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Radiation therapy plays an important role as a curative modality in the management of most solid tumors, but its therapeutic use may be associated with the development of 
second malignancies [1,2]. Radiation-induced second malignancy 
is a stochastic effect. The criteria for the diagnosis of a radiation-
induced secondary malignancy include the development of 
tumor in the previously irradiated field, histology of the second 
malignancy should be different from that of the original tumor 
and long latency period of at least 3 years after radiotherapy [3,4]. 
Radiation therapy in the management of central nervous system 
tumors may induce the second malignancies such as gliomas, 
meningiomas, and sarcomas [1,2,5,6]. Fibrosarcomas are the most 
common radiation-induced tumors after therapeutic radiation in 
the central nervous system.
Osteosarcoma is an uncommon complication of radiation 
treatment for brain tumors. Majority of the osteosarcomas arise 
de novo in bones; approximately 5.5% of all osteosarcomas are 
due to exposure to radiation. The risk of developing a radiation-
induced osteosarcoma is estimated at 0.01–0.03% among all 
irradiated patients [6,7]. The most common site is the skull. 
Surgery and chemotherapy have been the mainstay of treatment 
modalities for osteosarcomas secondary to radiation exposure. 
However, postirradiation osteosarcoma is associated with a poor 
prognosis [8,9].
Herein, we report a case of a 58-year-old man who developed 
osteosarcoma of the occipital bone 5 years after radiation 
treatment for oligodendroglioma in the right temporal lobe and 
was treated with surgery and chemotherapy.
CASE REPORT
A 58-year-old man had presented to the hospital with a chief 
complaint of seizures in June 2009 and evaluation had revealed 
space-occupying lesion in the right temporal lobe. The right 
temporal craniotomy and excision of the lesion were done in 
November 2009. Post-operative histopathology was suggestive 
of the oligodendroglioma World Health Organization (WHO) 
Grade 2. He received adjuvant radiotherapy of 54 Gy in 28 
fractions from January 2010 to February 2010 through two lateral 
portals in two phases (Fig. 1) (Phase 1: 50 Gy in 25 fractions 
at 2 Gy per fraction; Phase 2: 4 Gy in 2 fractions at 2 Gy per 
fraction). The patient also received concurrent chemotherapy 
with temozolomide during radiation therapy. He also received 
adjuvant chemotherapy with (procarbazine, lomustine, and 
vincristine) for 6 cycles from March to September 2010. Then, 
he was asymptomatic for 5 years. Contrast-enhanced computed 
tomography (CECT), done in September 2014, showed no 
evidence of tumor recurrence or any other lesion.
The patient presented again in September 2015 with complaints 
of painless, progressive swelling in the right occipital region for 
the past 6 months. On examination, there was a diffuse 6 cm × 
3 cm × 3 cm swelling in the right occipital region with a small 
ulcer in the skin. The swelling was firm to hard in consistency. The 
patient was ambulant and was not having any neurological deficit. 
Ophthalmological examination revealed visual acuity of 6/9 in the 
right eye and 6/18 in the left eye with no evidence of papilledema.
CECT showed gliotic changes in the right parietotemporal 
region; lytic destruction of the right parietal and occipital 
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bone with diploic expansion and mildly enhancing intracranial 
(extradural plane) and extracranial (galeal plane) soft tissue 
(Fig. 2). Magnetic resonance imaging (MRI) study demonstrated 
multiloculated cystic lesion with septal enhancement and no 
increased cerebral blood volume (CBV), no restriction of 
diffusion, in the right superior temporal lobe, possibly radiation 
necrosis, and enhancing soft tissue lesion in the right occipital 
extracranial and extradural region, with destruction of the 
underlying occipital bone showing focal increased CBV (Fig. 3).
The patient underwent excision of the right occipital lesion 
and titanium mesh cranioplasty in December 2015. Immediately 
after raising the scalp flap, a large amount of necrotic material 
came out and the undersurface of scalp was found to be infiltrated. 
The infiltrated portion of the scalp along with the ulcerated skin 
margins was excised. The dura was found to be grossly intact and 
transverse sinus was identified. Titanium mesh cranioplasty was 
done and the wound was closed primarily in layers. Histological 
examination revealed neoplasm composed of spindled to polygonal 
cells in sheets. The cells showed moderate nuclear pleomorphism, 
increased nuclear-cytoplasmic ratio and active mitosis including 
atypical forms. There was the presence of malignant osteoid, 
focal myxoid change, and vast areas of necrosis. The tumor 
cells are glial fibrillary acidic protein negative with high MIB-1 
labeling index (20–25%). The histological diagnosis was the right 
occipital osteosarcoma.
Post-operative CECT showed significant decompression 
of tumor with no intradural residual lesion with titanium mesh 
cranioplasty in situ. However, contrast MRI study showed a 4.8 
× 1.9 cm sized T1 hypointense, T2/fluid-attenuation inversion 
recovery isointense extra-axial biconvex enhancing lesion in the 
right occipital region; it also showed multiseptated cystic lesion in 
the right temporal region with no significant choline elevation in 
magnetic resonance spectroscopy, features suggestive of radiation 
necrosis. CECT thorax and bone scan were done to rule out lung 
and bone metastases, respectively, and they were essentially 
normal. The patient underwent 3 cycles of chemotherapy with 
doxorubicin 60mg/m2 D1 and ifosfamide 1.5g/m2 D1–D3. 
MRI imaging revealed a mild reduction in the occipital lesion. 
Then, he received 3 more cycles of chemotherapy, but there 
was a progression of the local disease, and the patient died in 
August 2016, probably because of raised intracranial tension and 
significant mass effect.
DISCUSSION
Radiation therapy plays a significant role as adjuvant therapy 
in many brain tumors. However, its utility may be associated 
with a rare complication of secondary malignancies [1,2]. As 
mentioned above, the diagnostic criteria for radiation-induced 
second malignancy include three criteria, and in the present case, 
the patient fits all the criteria, thus confirming the diagnosis of 
radiation-induced second malignancy.
The latent period is defined as the interval between 
irradiation of an initial tumor and development of postirradiation 
tumors. This latency is influenced by the dose and the size of 
the radiation field. High dose of radiation and large radiation 
volume may be associated with a short latent period. When we 
analyzed the literature, we found that the average latent period 
for the development of meningioma is 18.4 years when high-dose 
Figure 1:  Radiation portals
Figure 2: Contrast-enhanced computed tomography showing the 
lesion
Figure 3: Magnetic resonance imaging showing the lesion
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radiation is given and 36.8 years when low-dose radiation is given. 
The average latent period for the development of osteosarcoma 
is about 9.1 years [5,6,10]. In our case, the patient developed 
osteosarcoma of the occipital bone adjacent to the primary 
lesion but within the irradiated field, approximately 5 years after 
radiation treatment for the brain tumor.
Development of osteosarcomas after radiation therapy for 
brain tumors such as craniopharyngioma, pituitary adenoma, 
medulloblastoma, and gliomas has been reported in the 
literature [11]. Watanabe et al. [12] reported radiation-induced 
osteosarcoma of the left parietal and occipital bone 16 years after 
surgery and radiation for glioma in the right occipital lobe, but the 
type of glioma was not known. Till now, the largest series had been 
reported by Patel et al. [13] in which they identified 16 patients 
with radiation-induced osteosarcomas of the calvarium and skull 
base, of which two patients had received initial radiation therapy 
for oligodendroglioma. In our case also, the patient developed 
osteosarcoma in the occipital bone after receiving radiation 
therapy for oligodendroglioma.
Surgery and chemotherapy have been the mainstay 
treatment modalities for osteosarcoma of the skull. However, 
postirradiation osteosarcoma is associated with a poor prognosis 
due to high rates of local recurrence [3,14]. In our case also, 
the patient underwent excision of the right occipital lesion and 
titanium mesh cranioplasty and received 6 cycles of adjuvant 
chemotherapy with doxorubicin and ifosfamide, but the patient 
developed progression of a local disease and died. The median 
survival for patients with postirradiation osteosarcomas ranges 
from 12 to 18 months, and it decreases to <12 months for those 
with intracranial extension [8,9].
CONCLUSION
Radiation-induced malignancy is one of the most deadly long-term 
complications of therapeutic radiation exposure. Since the role of 
radiation therapy in the radical treatment of most solid tumors 
continues to evolve and the survival of cancer patients continues 
to increase, it is mandatory for the treating radiation oncologist 
to be aware of the postirradiation secondary malignancies and 
to counsel and to monitor the patients for the occurrence of this 
uncommon complication.
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